Summary
Neuroblastoma is a type of cancer that primarily affects children. In some cases, the tumor is driven by a genetic mutation in a protein called ALK, and doctors use a targeted drug named lorlatinib to stop it. Unfortunately, the cancer often learns to outsmart the treatment. To understand how this happens, scientists recently established a novel cancer cell line, named PUMC-NB1, from a pediatric patient's tumor. These lab-grown cells carry a specific ALK mutation, giving researchers a realistic model to study the disease.
By pushing these cells to develop resistance to the drug, the research team discovered the cancer's clever backup plan. When lorlatinib blocks the ALK protein, the tumor relies on a completely different protein called EGFR to survive. The cancer cells ramp up their production and activation of EGFR, creating a molecular detour that allows them to keep growing even when their main pathway is shut down.
The scientists then tested a way to block this escape route. They found that combining lorlatinib with afatinib, a drug that specifically inhibits EGFR, synergistically halted the growth of the resistant cancer cells. However, these findings are still in the early preclinical stages. The experiments were limited to cells in a lab dish and a small-scale trial involving five mice, meaning clinical trials are still needed to confirm if this two-drug combination is safe and effective for human patients.
Why it matters.
Drug resistance is one of the most devastating challenges in pediatric cancer care. When a child's tumor stops responding to a targeted therapy, their treatment options become severely limited. This research is significant because it not only uncovers the exact biological mechanism behind the resistance but also proposes a tangible solution. By identifying EGFR as the cancer's escape hatch, doctors can potentially anticipate treatment failure before it happens.
Furthermore, this study highlights the growing promise of combination therapy in modern medicine. Instead of spending years developing an entirely new drug to fight resistant tumors, oncologists might be able to repurpose existing therapies like afatinib to corner the disease. If future clinical trials validate these early preclinical results, this dual-targeting approach could eventually provide a critical lifeline for children battling relapsed neuroblastoma.
The story in numbers.
- Tumor formation rate in NOD-SCID mice
- 100%
- IC50 of lorlatinib for PUMC-NB1 cells
- (0.04±0.01) μmol/L
- Combination index for afatinib and lorlatinib co-treatment
- <1
Follow the evidence.
This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.